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1. INTRODUCTION 
Estrogen receptors (ERs) belong to the steroid hormone superfamily of nuclear receptors 
(NRs) (Katzenellenbogen et al.,1996). Other types of steroid receptors among the NRs 
include the estrogen-related receptors (EER), progesterone receptors (PR), androgen 
receptors (AR), glucocorticoid, and mineral corticoid receptors. Steroid receptors (SRs), act 
as ligand-dependent transcription factors, and their activity is associated with the cell cycle 
(Lee et al.,2012; Kim et al.,2012). Estrogens, acting via the ER, play important roles in 
regulating the growth, differentiation, and functioning of many reproductive tissues including 
the uterus, vagina, ovary, oviduct, and mammary gland. In the uterus and mammary gland, 
estrogens increase proliferation and alter cell properties via, at least in part, the induction of 
growth factors and growth factor receptors, an effect largely antagonized by antiestrogens 
(Katzenellenbogen et al.,1996).  Moreover, estrogen is an important sex hormone produced 
primarily in the ovaries in females and testes in males. This steroid hormone regulates the 
growth, development, and physiology of the reproductive system in humans.   
Estrogens have important sites of action in the pituitary, hypothalamus, and specific brain 
regions (Katzenellenbogen et al.,1996).  Estrogen also affects the neuroendocrine, skeletal, 
adipogenic, and cardiovascular systems (Lee et al.,2012; Kim et al.,2012,). ERs are found 
mainly in the nucleus, but also in the cytoplasm and mitochondria (Jia et al.,2015; Wright et 
al.,2015). Estrogens have been shown to protect against neurodegenerative diseases and 
injury, including stroke (Westberry et al.,2008).Biological functions of estrogen are mediated 
by binding to the ERs estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). 
Estrogen signaling is selectively stimulated or inhibited depending upon a balance between 
ERα and ERβ activities in target organs. ERα was cloned from human breast cancer MCF-7 
cells in 1986 and ERβ was cloned from  rat  prostate in 1996 (Lee et al.,2012; Kim et 
al.,2012,). ERα and ERβ genes are located on different chromosomes 6q25.1 and 14q23.2 
(Jia et al.,2015; Wright et al.,2015). 
The proposed functions of ERβ include antiproliferative action, regulation of apoptosis, 
control of antioxidant gene expression, and modulation of immune responses, anxiety related 
behavior, and the risk of heart failure. In many respects, ERβ acts as an indispensable 
hormone receptor for maintenance of the proper functions of vital organs (Leung et al.,2006). 
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ER activates intracellular signaling pathways that indirectly affect genomic activity via other 
transcriptional regulators such as cyclic-AMP response element binding protein (CREB). 
CREB is abundantly expressed in the brain, particularly in neurons. Phosphorylation at the 
ser-133 position of CREB followed by recruitment of CREB binding protein (CBP) activates 
CRE-mediated gene transcription. Various extracellular stimuli cause phosphorylation of 
CREB (pCREB) via Protein Kinase A, extracellular signalrelated kinase (ERK), and 
calcium–calmodulin dependent protein kinase (CaMK). Antiinflammatory and 
neuroprotective activity of estradiol, neuroprotection after ischemia, inhibition of microglial 
activation, and inhibition of high MMP-9 levels. In addition, a growing number of studies 
have reported antiinflammatory roles for ERβ, such as neuroprotection after ischemia, 
inhibition of microglial activity, suppression of transcription, and decreased levels of IL-1b, 
IL-6, TNFα, and chemokine CCL2 (Asl et al.,2013; Khaksari et al.,2013). 
ERβ agonists in mice demonstrated that neuroprotection following global ischemia is 
mediated by ERβ (Carswell et al., 2004). More recently ERβ agonists were shown to have no 
effect following focal ischemia in rats (Farr et al., 2007). The role of ERβ could be due to the 
type of ischemia or differences between rats and mice. Studies using ERα knockout females, 
however, demonstrate that neuroprotection by estradiol following focal ischemia is dependent 
on the presence of ERα in the cortex (Dubal et al., 2001), and that ERβ alone is not sufficient 
for neuroprotection in females. 
In the present study, the neuroprotective effect of novel ERβ agonists will be evaluated in 
middle cerebral artery occlusion model. To explore the behavioural alteration: grip strength, 
open field test, elevated plus maze will be performed. The neuroinflammation will be 
assessed by quantifying TNFα and IL1β (ELISA). The anti apoptotic activity will be 
evaluated by caspase activity assay and quantification of Bax/Bcl2 level (Western blot). 
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2.LITERATURE REVIEW 
Estrogen Receptor 
Estrogen receptors (ERs) belong to the steroid hormone superfamily of nuclear receptors 
(NRs) (Katzenellenbogen et al.,1996). Other types of steroid receptors among the NRs 
include the estrogen-related receptors (EER), progesterone receptors (PR), androgen 
receptors (AR), glucocorticoid, and mineral corticoid receptors. Steroid receptors (SRs), act 
as ligand-dependent transcription factors, and their activity is associated with the cell cycle 
(Lee et al.,2012; Kim et al.,2012). Estrogens, acting via the ER, play important roles in 
regulating the growth, differentiation, and functioning of many reproductive tissues including 
the uterus, vagina, ovary, oviduct, and mammary gland. In the uterus and mammary gland, 
estrogens increase proliferation and alter cell properties via, at least in part, the induction of 
growth factors and growth factor receptors, an effect largely antagonized by antiestrogens 
(Katzenellenbogen et al.,1996).  Moreover, estrogen is an important sex hormone produced 
primarily in the ovaries in females and  testes in males. This steroid hormone regulates the 
growth, development, and physiology of the reproductive system in humans. Estrogens have 
important sites of action in the pituitary, hypothalamus, and specific brain regions 
(Katzenellenbogen et al.,1996).  Estrogen also affects the neuroendocrine, skeletal, 
adipogenic, and cardiovascular systems (Lee et al.,2012; Kim et al.,2012). ERs are found 
mainly in the nucleus, but also in the cytoplasm and mitochondria (Jia et al.,2015; Wright et 
al.,2015). Estrogens have been shown to protect against neurodegenerative diseases and 
injury, including stroke (Westberry et al.,2008). 
ER Subtypes 
Biological functions of estrogen are mediated by binding to the ERs estrogen receptor alpha 
(ERα) and estrogen receptor beta (ERβ). Estrogen signaling is selectively stimulated or 
inhibited depending upon a balance between ERα and ERβ activities in target organs. ERα 
was cloned from human breast cancer MCF-7 cells in 1986 and ERβ was cloned from  rat  
prostate in 1996 (Lee et al.,2012; Kim et al.,2012). ERα and ERβ genes are located on 
different chromosomes 6q25.1 and 14q23.2 (Jia et al.,2015; Wright et al.,2015). 
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ERβ belongs to the nuclear receptor superfamily. It is classified as a type I nuclear receptor, 
because it resides in cytosol and undergoes nuclear translocation after ligand binding. ERβ is 
expressed in a variety of normal and malignant tissues, some of which express ERα .The 
proposed functions of ERβ include antiproliferative action, regulation of apoptosis, control of 
antioxidant gene expression, and modulation of immune responses, anxiety related behavior, 
and the risk of heart failure. In many respects, ERβ acts as an indispensable hormone receptor 
for maintenance of the proper functions of vital organs (Leung et al.,2006). 
Different between ERα and ERβ 
ERα and ERβ contain different ligand binding domains, and each receptor is encoded by a 
different gene. This receptors also signal differently at the AF-1 site in the presence of 
Estrogen, the Estrogen activates transcription at ERα, it inhibits transcription at ERβ, 
respectively. ERα and ERβ receptors have been implicated to mediate genomic signaling as 
well as non-genomic signaling in cells. Another important difference between ERα and ERβ 
is tissue distribution, ERα is expressed in breast, ovary, uterus, and brain, while ERβ is 
expressed in bone, heart, lungs, kidney, endothelial cells and brain. In the brain,ERα is 
localized most densely in the hypothalamus, hippocampus, and preoptic area, with moderate 
to light density in the cerebral cortex. ERβ localization has been documented predominantly 
in the cortex, throughout the hippocampus, in the olfactory bulb, septum, preoptic area, 
nucleus of striata terminalis, amygdala, paraventricular hypothalamus, thalamus, ventral 
tegmental area, substantia nigra and cerebellum (Brann et al.,2012; Raz et al.,2012). 
ROLE OF ER IN ISCHEMIC STROKE 
Estrogens are steroid hormone known to play a crucial role in the cellular events involved in 
development and maintenance of normal body function throughout a lifetime by acting on a 
vast variety of target tissues(Morissette et al.,2008; Saux et al.,2008). Estrogen has potent 
neuroprotective effects in animal models of brain disease or injury via various mechanisms 
such as anti-inflammation, reduction of oxidative stress and excitotoxicity, anti-apoptosis and 
vasodilation in the ischemic brain. 
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Estrogens have been shown to protect against neurodegenerative diseases and injury, 
including stroke. Permanent middle cerebral artery occlusion (MCAo) is a wellestablished 
model of focal ischemic stroke in rodents. Following MCAo, there is a reduction in cerebral 
blood flow, which leads to cell death in the striatum followed by damage to cells in the 
overlying cortex (Namura et al., 1998; Liu et al., 1999). In this model, gonadectomized 
females (Simpkins et al., 1997; Dubal et al., 1998) and males (Toung et al., 1998; Alkayed et 
al., 1998) have a much larger MCAo-induced cell loss than animals with higher circulating 
estrogen concentrations. Pre-treatment with even low doses of 17-β estradiol is sufficient to 
exert dramatic protection in the brains of both female (Dubal et al., 1998; Dubal et al., 2001) 
and male rats (Toung et al., 1998). Many of estrogen’s actions occur via two nuclear 
receptors, estrogen receptor alpha (ERα) (Koike et al.,1987) and the more recently discovered 
estrogen receptor beta (ERβ) (Kuiper et al.,1996). These receptors are important for 
neuroprotection by estrogen. Generalized pharmacologic blockade of estrogen receptors 
exacerbates ischemic injury in mice (Sawada et al.,2000) and blocks estrogen-induced 
neuroprotection in cultured neurons (Singer et al., 1999; Wilson et al.,2000) and in cortical 
explant cultures (Wilson et al.,2000). Another study using ERα knockout mice also suggested 
that in male ERα knockout mice, the absence of ERα did not increase the ischemia-induced 
damage, but these males were not given estradiol (Sampei et al., 2000). In both male and 
female rodents, ERα mRNA expression is high in the neonatal cortex, but dramatically 
decreased to only a few cells in the uninjured adult cortex. Twentyfour hours after MCAO, 
however, ERα mRNA and protein are significantly increased in the cortex of female rats and 
mice (Dubal et al., 1999, 2006). In ovariectomized (OVX) females, this increase in ERα 
expression occurs in both oil and estradiol-treated groups, but is seen earlier after injury with 
estradiol treatment (Dubal et al., 2006). These data suggest that in females, the ischemia-
induced increase in ERα expression in the cortex is necessary for the neuroprotective effects 
of estradiol. In males, the injury induced regulation of ERα and the mechanisms of estradiol 
action are still largely unknown. ERβ agonists in mice demonstrated that neuroprotection 
following global ischemia is mediated by ERβ (Carswell et al., 2004). More recently ERβ 
agonists were shown to have no effect following focal ischemia in rats. The role of ERβ 
could be due to the type of ischemia or differences between rats and mice. Studies using ERα 
knockout females, however, demonstrate that neuroprotection by estradiol following focal 
ischemia is dependent on the presence of ERα in the cortex (Dubal et al., 2001), and that ERβ 
alone is not sufficient for neuroprotection in females. 
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STROKE 
The two broad categories of stroke, hemorrhage and ischemia,they are diametrically opposite 
conditions. Hemorrhage is characterized by too much blood within the closed cranial cavity, 
while ischemia occurs when the amount of oxygen and other nutrients supplied by blood flow 
is insufficient to meet the metabolic demands of brain tissue (Tuttolomondo et al.,2012; 
Raimondo et al.,2012). such as glucose,critical for survival of central nervous system (CNS) 
cells (Tobin et al.,2014; Bonds et al.,2014). 
Ischemic Stroke 
The most common type of stroke is called ischemic stroke or cerebral infarction. According 
to recent data released by the American Heart Association, 87 % of strokes are classified as 
ischemic(Roger et al.,2012; Go et al.,2012). Infarcts occur as a result of insufficient or 
interrupted flow of blood to an area of  the brain, typically caused by blockage of an artery . 
Brain tissue must be supplied with oxygen, glucose, and other vital materials by the constant 
influx of blood at a rate of about 50–54 ml of blood per 100 g of brain tissue per minute. 
Brain cells deprived of adequate blood flow (cerebral blood flow [CBF] below 15–20 ml 
blood flow/100g tissue/min) will become ischemic(Astrup et al.,1981; Symon et al.,1981) 
their membrane pumps will begin to fail, intracellular processes will break down, and the 
brain tissue becomes swollen. Importantly, the ischemic brain tissue may still be salvageable 
if perfusion can be restored at this point . If the hypoperfusion worsens (i.e., CBF <8–10 
ml/100 g/min) (Hossmann et al.,1994), this tissue at risk will become irreversibly damaged 
with cell death proceeding within 4–8 min. This event is referred to as an ischemic stroke . 
Damage to brain tissue will occur initially in the region contiguous to the blocked artery (the 
so-called infarct core), while a penumbra of at-risk tissue surrounding this region remains 
viable for some time following onset of ictus and with timely intervention may respond to 
efforts to restore blood flow to the region(Astrup et al.,1981; Symon et al.,1981). 
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MECHANISM OF ISCHEMIC STROKE 
FIGURE .1. 
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TYPES OF ISCHEMIA 
Focal ischemia:Focal ischemic stroke occurs when cerebral blood flow is attenuated in a 
specific brain region (Hata et al.,2000; Maeda et al.,2000).Dependent on the nature of the 
occlusion in the cerebral artery, focal ischemic stroke can be further subdivided into 
thrombotic or embolic stroke(Adams et al.,1993; Amarenco et al.,2009). 
Thrombotic stroke occurs when a blood clot is formed within a cerebral artery, which is 
commonly caused by atherosclerosis where the vascular endothelium is constantly damaged 
resulting in the activation of numerous vasoactive enzymes that leads to the formation of an 
atherosclerotic plaque within the cerebral artery. Furthermore, additional pathological 
changes in atherosclerosis such as thrombosis, ulceration and calcification increases the risk 
of blood clot formation. Other pathological conditions such as hypercoagulable states, 
fibromuscular dysplasia, arteritis and arterial trauma can comparably lead to thrombotic 
strokes (Broussalis et al.,2012; Killer et al.,2012). 
Embolic strokes occurs when a blood clot or atherosclerotic plaque fragment that is formed 
elsewhere in the circulatory system detaches and is mobilized through the blood stream and 
occludes a cerebral artery. The most common artery to be occluded by an embolus are the left 
and right middle cerebral arteries since 80% of blood volume that travels through the arteries 
in the neck eventually flows through the middle cerebral artery (Demaerschalk et al.,2010) 
Global ischemia: Global ischemic stroke occurs when blood flow to the entire brain or a 
majority part of the brain is stopped or severely reduced due to hemodynamic changes in the 
peripheral circulatory system (Böttiger et al.,1999; Teschendorf et al.,1999). 
Ischemic Stroke Models 
Several focal cerebral ischemic stroke models have been developed in a variety of species; 
these include mechanical occlusion of the middle cerebral artery (MCA), thrombo embolic 
models, and photothrombotic models. Global ischemia models, although not formally stroke, 
are divided into complete and incomplete models of ischemia, which are produced by 
occluding the cerebral blood flow (CBF) completely or incompletely (Yan et al.,2015;  
Chopp et al.,2015). 
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Animal models of ischemic stroke (Yan et al.,2015;  Chopp et al.,2015) 
 
TABLE.1. 
Types Means of induction Characteristics 
 
Focal  ischemic  models 
Mechanical  Mcao models 
Surgical clips 
 
MCA ligation 
 
Eletrocoagulation 
 
 
Intraluminal filament 
MCAO 
 
Embolic 
Thrombotic 
 
 
Microspheres 
 
 
 
Photothrombotic 
 
 
Endothelin-1 
 
 
 
Clip proximal MCA 
 
Ligate the MCA 
 
Interrupt MCA blood flow by 
electrocoagulation 
 
Insert filament to origin of MCA 
 
 
 
Occlude MCA by thrombotic 
clot made with autologous blood 
 
Inject calibrated compounds and 
artificial microspheres into 
MCA 
 
Inject photosensitive dye 
 
 
Apply ET-1 to exposed MCA 
 
 
 
Technical feasibility and 
consistent histological results 
Lesion limited to cortex 
 
Induces distal and proximal 
MCAO 
 
Reproduces cerebral ischemia 
and reperfusion injury 
 
 
 
Best model for study of 
thrombolytic agents 
 
Different sizes of emboli 
induce different ischemic 
events 
Facilitates behavioral studies 
of ischemia in specific 
anatomical-functional regions. 
Induces dose-dependent 
reduction in local blood flow 
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Global ischemic models 
4-VO 
 
2-VO 
 
 
3-VO 
 
 
Ventricular fibrillation 
 
 
Neck tourniquet 
 
Ligate carotid artery and 
vertebral arteries 
 
Ligate bilateral carotid arteries 
 
Occlude common carotid and 
basilar arteries 
 
Induce cardiac arrest with 
ventricular fibrillation 
 
Inflate high-pressure cuff to 
occlude bilateral 
 
Induces reversible bilateral 
forebrain and brainstem 
Ischemia 
 
Induces reversible forebrain 
ischemia 
Better control of CBF than 4-
VO 
 
 
To study mechanisms of CA-
induced delayed neuronal 
death. 
 
Leads to variable ischemic 
outcomes. 
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Pathology of ischemia 
FIGURE .2. 
 
 
 
Important inflammatory mediator in ischemic stroke 
After brain injury, up regulated inflammation mediator and immune cell infiltrate in the 
pathophysiology of cerebral ischemia acts as a complex role. This includes a series of 
proinflammatory mediators and anti-inflammatory mediators; it has a different role in the 
occurrence and development of ischemic stroke (Jin et al.,2013; Lin et al.,2013; Zhang et 
al.,2013; Nanda et al.,2013). 
 
 
                                                                                              Literature review 
 
Department of Pharmacology, PSG College of Pharmacy Page 12 
 
Proinflammatory mediators 
IL-1α and IL-1β, IL-1α and IL-1β knockout mice in the middle cerebral artery occlusion can 
reduce brain damage. The main function of IL-1α and IL-1β was achieved by IL-1R1 and IL-
1R2 (Rothwell et al.,2000;  Luheshi et al.,2000). 
ICAM-1 is one of the members of the immunoglobulin super family is a major 
proinflammatory cytokines, in stroke-related research, animal experiments showed that 
increased expression of ICAM-1 is related to the pathogenesis of ischemic lesions , while 
blocking or knockout ICAM-1 will reduce brain damage and improve stroke 
outcomes. Clinical studies soluble ICAM-1 is up-regulated and reached a peak in acute 
ischemic stroke within 24 hours. ICAM-1 also significantly up regulated in brain tissue after 
cerebral ischemia, but the real role of ICAM-1 in stroke still remained controversial (Shyu et 
al.,1997; Chang  et al.,1997;  Lin et al.,1997). 
Chemokines Monocyte chemo attractant protein-1 (MCP-1), macrophage inflammatory 
protein -1(MIP-1α) and chemokine (CX3CL1), these three are the most common 
proinflammatory chemokines, up regulated in cerebral ischemia animal models , ischemic 
chemokine up regulation is seen as deleterious effect . Related studies have shown that MCP-
1, MIP-1α, and CX3CL1 promote stroke pathological process; inhibiting or defect itself can 
reduce ischemic brain damage. MMPs Previous studies showed that matrix metallo 
proteinases (MMPs) and neurogenic migration are related, inhibition of MMPs activity may 
reduce brain damage .  In the later phase of stroke due to MMP-9 associated with many 
growth factors, which are closely related with angiogenesis, therefore it is also beneficial for 
stroke (Soriano et al.,2002; Amaravadi et al.,2002). 
Anti-inflammatory mediators  
IL-10 Interleukin-10 (IL-10) is an anti-inflammatory cytokine, increased in the brain tissue 
after a stroke, at the same time plays an important role in the pathogenesis of stroke. Related 
studies show that IL-10-deficient mice have wider range of brain damage in middle cerebral 
artery occlusion , in animal models, after increased IL-10, the level of brain damage was 
decreased after the stroke (Kim JS et al.,1996; Yoon SS et al.,1996) , clinical studies have 
shown that low levels of IL-10 would indicate increased risk of stroke (van et al.,2002; 
Gussekloo et al.,2002).  
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TGF-β mRNA increased within 6 hours after stroke, the increasing levels last for 15 days 
after the stroke (Klempt et al.,1992), transforming growth factor-β(TGF-β) has Anti-
inflammatory and neuroprotective effect in stroke, which may become effective stroke 
treatment strategies. TGF-β can reduce ischemic damage and reduce the associated 
inflammation , TGF-β blockade will aggravate ischemic brain damage (Johnston et al.,2001; 
Carter et al.,2001; Freed et al.,2001). 
TIPE2 (Tumor necrosis factor-a-induced protein 8-like 2) is an anti-inflammatory protein, has 
an important role in maintaining the steady-state within the immune system ,mice with 
knockout TIPE2 will induce multi-organ inflammation and splenomegaly, studies show that 
TIPE2 has high expression in cerebral ischemia, but also has a role in the pathogenesis of 
stroke, blocking TIPE2 in mice that with middle cerebral artery occlusion can increase infarct 
size, neurological disorders, inflammatory cytokine expression, and inflammatory cell 
permeability (Zhang et al.,2012; Wei et al.,2012;  Liu et al.,2012;  Liu et al.,2012). 
IGF-1 In an animal model, Insulin-like growth factors-1(IGF-1) having a neuroprotective 
effect after a stroke and can reduce infarct size and improve cell survival studies show that 
high levels of IFG-1 in serum during the early stage of ischemic stroke is closely related to 
neurological recovery and better functional outcome (Jin et al.,2013; Liu et al.,2013; Zhang 
et al.,2013; Nanda et al.,2013). 
Iinflammation regulation are closely related; NF-kB pathway is more complex, NF-kB 
promotes neuronal death in cerebral ischemia. In cerebral ischemia NF-kB expression up 
regulated, the activation of NF-kB will become the agonists of TNF-a, IL 6 (Hallenbeck et 
al.,2002). Inhibition of autophagy can reduce the activity of NF-kB pathway, blocking the 
formation of autophagy small bodies and inhibition of lysosomal proteases, will reduce IkBa 
and NF-kB target gene expression. Autophagy degradation and inhibiting the 
phosphorylation to regulate IKK-b activity. The similarity such as TNF-α, IL-1 β and other 
cytokines were regulated by autophagy and produced during the inflammatory 
process. Beclin1, Beclin2 interacting protein is a key component in PI3K, it is very crucial 
during the formation of autophgic bodies (Wang et al.,2002) . In Jiang Y’s studies believe 
that tetracycline inhibit ischemic brain tissue autophagic activity, on this basis further to 
suppress the inflammatory process by reducing NF-kB pathways (Jiang et al.,2012;  Zhu et 
al.,2012;  Wu et al.,2012;  Xu et al.,2012). 
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3. OBJECTIVES & PLAN OF STUDY 
The objective of the study is 
1. To assess behavioural and not studied functions of ER-β agonist in cerebral ischemic 
condition. 
2. To evaluate the mechanism of ER-β agonist in cerebral ischemia by exploring the anti-
inflammatory and apoptotic pathways. 
 
PLAN OF STUDY 
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Phase-1 
Surgical optimization and ischemia inducement by MCAo (middle cerebral artery occlusion) 
model in SD rats. 
Phase-2  
The following neurobehavioural parameter were studied to assess the effect of new leads 
in the MCAo model  
2.1  Neurological deficit score (Zhang et al.,2016) 
2.2  Gripstength (Leach et al.,1993; Esler et al.,1993) 
2.3  Locomotor activity (Borlongan et al.,1995) 
2.4  Elevated plus maze (EPM) (Vécsei et al.,1991; Beal et al.,1991) 
Phase-3 
The mechanism of action of neuroprotective action of ERβ agonist were evaluated by 
measuring the following biochemical markers through  
3.1 Western blot   
Bax, bcl2 
3.2 Elisa 
IL-1β,TNF-α. 
3.3 Caspase-3 activity assay 
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4. MATERIALS & METHODS 
MATERIALS: 
TABLE.2. 
 
Chemicals &tools used                                                            Company name                          
Crushing forceps          Finetools 
Bonney forceps                                                      Finetools 
Adson tissue forceps                                                      Finetools 
Adson teeth forceps                                                      Finetools 
Horton adson forceps                                                      Finetools 
Retractors                                                                  Finetools 
Scalpels                                                                  Finetools 
Microvessel clips                                                      Finetools 
Scissors                                                                   Finetools 
Silicone gel                       Anabond 
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Methods:  
4.1. Animals  
Male Sprague-Dawley rats (200-240g) used in the study were housed in individual 
polypropylene cages in a well ventilated room (air cycle: 15/hr) under an ambient 
temperature of 23±2ºC and 40-65% RH, with a 12:12 h light/dark artificial photoperiod. They 
were provided with food and purified water. All the animals were acclimatized atleast for 
7days to the laboratory conditions prior to experimentation. Guidelines of “guide for the care 
and use of laboratory animals” were strictly followed throughout the study. Institutional 
animal ethical committee (IAEC), PSG Institute of medical science and research, 
Coimbatore, approved the study.  
ER-β Agonist 
FIGURE.3. 
 
 
                                            
 
TABLE .3. 
Compound  R  R1  
CMU  
CH3  -  
CUE  
-  C2H5  
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Groups and treatments : 
TABLE.4. 
     Number          Group           Treatment 
1 CONTROL  
2 MCAO   
3 MCAO + CMU 10mg/kg 
4 MCAO + CUE 10mg/kg 
 
4.2. Surgical procedure 
Focal cerebral ischemia was induced by middle cerebral artery occlusion with minor 
modifications. Rats were anesthetized with ketamine (90mg/kg) and xylazine (15mg/kg).The 
left common carotid artery was exposed at the level of external and internal carotid artery 
bifurcation. 4-0 nylon monofilament was used and its tip was made round headed by 
exposing it to flame. The Filament was coated with Anabond silicone gel and inserted into 
the external carotid artery and advanced to the internal carotid artery for a length of about 20–
21 mm until a slight resistance was felt. On achieving occlusion, the filament was held in 
place with ligature and the external incision was sutured temporarily. After 2 h of ischemia 
the rats were anesthetized, suture was opened, the filament was pulled out and reperfusion in 
internal carotid artery was ensured visually. Throughout the surgical procedure, body 
temperature was measured by inserting a thermometric probe into the rectum of rat and it was 
maintained at 37±0.5 °C using thermostatically controlled heating blanket. Animals were 
then kept in a cage with a heating lamp, which maintained the cage temperature between 
29±1 °C for another 1 h to counteract any possible hypothermic effect. In the sham-operated 
(SO) group, external carotid artery was surgically prepared for insertion of filament, but the 
filament was not inserted. 
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4.3. Neurobehavioral paradigms 
4.3.1. Neurological deficit (Zhang et al.,2016) 
Neurological deficit were assessed by following score pattern after 24 hrs of ischemic 
reperfusion (IR) 
Neurological deficits (6-point scale) 
• 0 = No neurological deficit 
• 1 = Failure to extend left forepaw fully 
• 2 = Circling behaviour 
• 3 = Falling to the right 
• 4 = No spontaneous walking with a depression 
• 5 = Death 
4.3.2. Loco motor activity 
The rats will be placed in the open field apparatus for recording the locomotion. The 
locomotor activity will be measured using an open field test. The behavioral parameters 
measured in open field test were Rearing, Grooming, No of ambulations, Time spent central 
compartment. 
4.3.3. Grip strength measurement 
Grip strength test by using bioseb grip strength meter was used to study of neuromuscular 
functions by determining maximal peak force developed by rodent were measured in units 
grams. 
4.3.4  Elevated plus maze 
The elevated plus maze test (EPM) consisted of two open arms (35 × 5 cm) crossed with two 
closed arms (35 × 5 ×20 cm). The arms were connected together with a central square of 5 × 
5 cm. The apparatus was elevated to the height of 50 cm in a dimly illuminated room. 
Animals were placed individually at the end of either of the open arms facing away from the 
central platform. The time taken by each animal to move from open arm to either of the 
closed arms was recorded. This duration of time was called transfer latency (TL). If the 
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animal did not enter into any of the enclosed arms within 120 s, it was gently pushed into any 
of the enclosed arms and TL was considered as 120 s. Later the animal was allowed to 
explore the plus maze for 5 min and send back to its home cage. 
4.4. Probable mechanism of neuroprotection 
4.4.1 Western blot  
Western Blot Analysis for Protein Detection Cells were lysed in RIPA buffer along with 
protease and phosphatise inhibitor cocktail. Samples were kept on ice for 15– 30 min 
followed by sonication and centrifugation at 12,000 rpm for 5 min. The supernatant solution 
was taken and assayed for total protein content by Bradford’s method. Equal protein 
concentration (20 μg) was used for SDS polyacrylamide gel electrophoresis. Proteins were 
transferred to a nitrocellulose membrane and blocked with 5 % bovine serum albumin 
prepared in TBST buffer for 3 h. The blocked membrane was incubated with primary 
antibody against Akt1 (1:750), S473 p-Akt1 (1:1000), GSK-3β (1:500), S9 p-GSK-3β 
(1:1000), β-catenin (1:500), and reference protein β-actin (1:1000) for 2 h at room 
temperature. Following that, goat anti-rabbit IgG-HRP and goat anti-mouse IgG1-HRP 
secondary antibodies were added to the membrane in separate procedures according to the 
primary antibody used in the previous step and incubated for 1 h at room temperature. The 
membrane was developed and detected by Gel Dock system, G: Box (Syngene, Frederick, 
MD, USA). Row volume was considered for analysis. 
4.4.2. Elisa 
The levels of TNF-α in the ischemic cortex tissue was detected using an enzyme-linked 
immune sorbent assay(ELISA) test as described previously (Hang et al., 2004). Briefly, 
animals were killed 1 h, 4 h, and 24 h after MCAO. The brains were removed and cerebral 
cortex, dissected. The cortex was immediately frozen and kept at −70 °C. The frozen brain 
tissue was homogenized using a homogenizer in 500 μl buffer containing phosphate buffered 
saline (PBS) pH 7.2 (1mmol/L phenyl methyl sulfonyl fluoride (PMSF), 1 mg/L pepstatin A, 
1 mg/Laprotinin, 1mg/L leupeptin) and centrifuged at 12,000g for20 min at 4 °C. Afterwards, 
supernatant was collected and total protein was determined by Micro BCA Protein Assay Kit. 
The level of TNF-α in ischemic cortex tissue supernatant was measured using an ELISA kit 
(Diaclone, France) specific for rat TNF-α. The measurement of TNF-α was performed step-
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by-step based on the protocol booklet of ELISA kit. The TNF-α contents were expressed as 
pg TNF-α/mg total protein (Hang et al., 2004). 
4.4.3. Caspase activity assay 
 Brain tissue were harvested and lysed in 500 µl of lysis buffer by incubating on ice for 10 
min. Centrifugation at 10,000×g for 2 min was done to remove cell debris. The supernatant 
extract was taken, and protein measurement was done by Bradford’s method. Total protein 
(100 µg) was used in 50 µl of cell lysis buffer. To this, 50 µl of 2× reaction buffer containing 
10 mMDTT and 5 µl of 4 mM of DEVD-pNA (caspase-3 substrate) was added and incubated 
at 37 °C for 90 min. Absorbance was measured at 405 nm by Multiskan™ GO multiplate 
reader(Thermo Scientific, Waltham, USA). The fold change in enzyme activity was 
measured. 
4.5. Statistics 
The data are expressed on mean ±SD. The results will be analysed through one-way analysis 
of variance (ANOVA) followed by Tukey’s multiple comparison test to assess the statistical 
significance of the differences among the study groups using Graph Pad Prism5. 
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5. RESULTS 
Phase 5.1: MCAo (Middle cerebral artery occlusion) surgery optimization 
 
FIGURE.4. Branches of common carotid artery (CCA) 
 
FIGURE.5.Insertion of the monofilament to ICA through ECA 
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Phase 5.2 Behavioural studies 
5.2.1. Neurological deficit score 
The neurological deficit in the MCAo rats was assessed after 24hrs IR and on 7th day after 
surgery. After 24hrs and on 7th day significant increase in neurological score in MCAo rats 
(p<0.001) was observed in comparison to control rats. Traumatic Treatment of CUE 
(10mg/kg), on 7th day showed significant decrease in neurological score in comparison to 
MCAo group. 
5.2.2. Grip Strength 
Data are expressed in force (gms). MCAo rats showed significant decrease (p<0.001) in 
muscle tone are evidently decrease in force applied on the grid when compared to vehicle 
treated rats. Treatment of NCE CMU (10mg/kg), CUE (10mg//kg) showed significant 
improvement in neurological score on noted by increase in force applied on grid comparison 
to MCAo rats. 
5.2.3. Open Field Test 
5.2.3.2. Effect on ambulations  
MCAo rats showed significant decrease (p<0.01) in number of ambulations is comparison to 
control rats indicates loss of exploration behaviour. CUE (10mg/kg) showed significant 
increase p<0.05 in ambulatiory behaviour in comparison to MCAo group indicating 
improved exploration activity. 
5.2.3.3. Effect on grooming & Central compartment exploration 
There was no statistical difference between the groups in grooming behaviour and central 
compartment exploration activity between the treatment groups was observed in comparison 
to control rats. 
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5.2.3.4. Effect on rearing  
MCAo rats showed significant decrease (p<0.01) in reaering activity when compared to 
control vehicle treated rats indicaties reduced exploration activity. There was no significant 
difference between MCAo and treatment groups was observed in rearing behaviour. 
5.2.3.5. Effect on licking 
MCAo rats showed significant decrease (p<0.05) in number of licking behaviour when 
compared to control rats. Other treatment groups licking behaviour remains unaltered. 
5.2.3.6. Effect on freezing 
MCAo rats exhibited significant increase (p<0.001) in freezing behaviour as observed by 
increase in freezing time when compared to control rats indicates depression. CMU 
(10mg/kg), CUE (10mg/kg) showed significant decrease in freezing time in comparison to 
MCAo rats.  
5.2.4. Elevated plus maze 
5.2.4.1. Effect on time spent in central compartment 
Data are expressed in seconds. MCAo rats (p<0.01) showed significant decrease in central 
compartment activity when compared to control rats indicating increased anxiety in the rat.  
There was no significant difference between MCAo and treatment groups was recorded in 
this parameters. 
5.2.4.2. Effect on number of entries in open arm & closed arm 
The number of entries made in open & closed arm of elevated plus maze was found to be 
similar across all the groups studied. 
5.2.4.4. Effect on time spent in open arm 
MCAo rats have shown significant decreased (p<0.001) time spent in open arm when 
compared to control rats denotes increased anxiogenicity. CMU (10mg/kg), CUE (10mg/kg) 
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treated rats showed significant increase in time spent in open arm in comparison to MCAo 
group indicating  the decrease in anxiety behaviour induced by ischemia. 
5.2.4.5. Effect on time spent in closed arm  
Data are expressed in seconds. MCAo rats (p<0.001) have spent more time in closed arm 
when compared to control rats. CMU (10mg/kg), CUE (10mg/kg) treatment resulted in 
significant decrease in time spent in closed arm in comparison to MCAo rats indicates 
attenuation of anxiety behaviour due to ischemia. 
5.2.4.6. Effect on time to reach closed arm 
Data are expressed in seconds. MCAo rats (p<0.001) showed significant decrease in time 
taken to reach closed arm in comparison to control rats indicates CMU (10mg/kg) ,CUE 
(10mg/kg) treatment reversed in this behaviour in comparison to MCAo rats. 
5.3 Mechanism of action of neuroprotective action of ERβ agonist 
5.3.1 Western blot 
5.3.1.1. Effect of drug treatment on ratio of BAX level 
Data are expressed in ratio. MCAo rats (p<0.001) demonstrated significant increase in BAX 
level when compared to control rats. CMU (10mg/kg), CUE (10mg/kg) treated rats had by 
reduced significant BAX level in comparison to MCAo rats. 
5.3.1.2. Effect of drug treatment on ratio of Bcl2 level 
Data are expressed in ratio. MCAo rats showed significant decrease (p<0.05) in Bcl2 level 
after ischemia in comparison to control rats. CUE (10mg/kg) treatment lead to significant 
increase in Bcl2 level when compared to MCAo group. 
5.3.2. ELISA 
5.3.2.1. Effect on pro-Inflammatory mediator(TNFα) by ELISA 
Data are expressed in pg/mg protein. MCAo rats (p<0.001) inducement in SD rats 
significantly increase in TNFα levels when compared to control rats denotes increase in 
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inflammatory activity. CMU (10mg/kg), CUE (10mg/kg) treatment showed significant 
decrease in TNFα levels in comparison to MCAo vehicle treated rats indicating decrease in 
inflammatory markers release. 
5.3.2.2. Effect on pro-inflammatory mediator (IL 1β) by ELISA 
Data are expressed in pg/mg protein. MCAo rats have shown significant increase (p<0.001) 
in IL 1β level in comparison to vehicle treated control rats indicates increase in inflammatory 
activity during CMU (10mg/kg), CUE (10mg/kg) treated rats have shown significant 
decrease in IL 1β  levels in comparison to MCAo rats indicaties alternation of  inflammatory 
response with Erβ NCE administration. 
5.3.3. CASPASE-3 ACTIVITY ASSAY 
5.3.3.1. Effect on caspase activity assay 
Data are expressed in specific activity/µg protein. MCAo rats showed significant (p<0.001) 
increase in caspase enzyme activity in comparison to control rats shown increase in apoptosis 
(cell death). CMU (10mg/kg), CUE (10mg/kg) treatment resulted in cell proliferation 
significant decrease in caspase enzyme activity in comparison to MCAo rats indicating 
decreased observed by apoptosis. 
   Behavioural Studies 
FIGURE.6. Neurological deficit score after 24 hrs   
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Data are expressed as mean ±SD (n=6).Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. ***denotes statistical significance 
of MCAo group compared with control group at p<0.001. 
FIGURE.7. Neurological deficit score on 7th day 
                         
Data are expressed as mean ±SD (n=6). ***denotes statistical significance of MCAo group 
compared with control group at p<0.001. #denotes statistical significance of CUE (10mg/kg) 
treated groups compared with MCAo group at p<0.05 respectively. 
Grip Strength 
FIGURE.8. Effect of drug treatment on grip strength 
                              
Data are expressed as mean ±SD (n=6). ***denotes statistical significance of MCAo group 
compared with control group at p<0.001. ##, ## denotes statistical significance of CMU 
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(10mg/kg), CUE (10mg//kg) treated groups compared with MCAo group at p<0.01, p<0.01 
respectively. 
 
Open Field Test 
FIGURE.9. Effect of drug treatment on time spent in central compartment 
                                
Data are expressed as mean ±SD (n=6).Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. There is no statistical significance 
between the groups. 
FIGURE.10. Effect of drug treatment on no of ambulations 
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Data are expressed as mean ±SD (n=6). **denotes statistical significance of MCAo group 
compared with control group at p<0.01. #denotes statistical significance of CUE (10mg/kg) 
treated groups compared with MCAo group at p<0.05 respectively. 
 
FIGURE.11. Effect of drug treatment on grooming 
 
                               
Data are expressed as mean ±SD (n=6).Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. There is no statistical significance 
between the groups. 
FIGURE.12. Effect of drug treatment on rearing 
                                
Data are expressed as mean ±SD (n=6).Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. **denotes statistical significance of 
MCAo group compared with control group at p<0.01. 
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FIGURE.13. Effect of drug treatment on licking 
                                
Data are expressed as mean ±SD (n=6).Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. *denotes statistical significance of 
MCAo group compared with control group at p<0.05. 
FIGURE.14. Effect of drug treatment on freezing 
                          
 
Data are expressed as mean ±SD (n=6).Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. ***denotes statistical significance 
of MCAo group compared with control group at p<0.001. #, ##denotes statistical significance 
of CMU (10mg/kg), CUE (10mg/kg) treated groups compared with MCAo group at p<0.05, 
p<0.01 respectively. 
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Elevated Plus Maze 
FIGURE.15. Effect of drug treatment on time spent in central compartment 
                      
Data are expressed as mean ±SD (n=6). **denotes statistical significance of MCAo group 
compared with control group at p<0.01. 
FIGURE.16. Effect of drug treatment on no of entries in open arm 
 
                                        
Data are expressed as mean ±SD (n=6).Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. There is no statistical significance 
between the groups. 
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FIGURE.17. Effect of drug treatment on no of entries in closed arm 
                           
Data are expressed as mean ±SD (n=6). There is no statistical significance between the 
groups.   
FIGURE.18. Effect of drug treatment on time spent in open arm 
                    
Data are expressed as mean ±SD (n=6).Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. ***denotes statistical significance 
of MCAo group compared with control group at p<0.001. #, # denotes statistical significance 
of CMU (10mg/kg), CUE (10mg/kg) treated groups compared with MCAo group at p<0.05, 
respectively. 
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FIGURE.19. Effect of drug treatment on time spent in closed arm 
                 
Data are expressed as mean ±SD (n=6). ***denotes statistical significance of MCAo group 
compared with control group at p<0.001. #, ## denotes statistical significance of CMU 
(10mg/kg), CUE (10mg/kg) treated groups compared with MCAo group at p<0.05, p<0.01  
respectively. 
FIGURE.20. Effect of drug treatment on time to reach closed arm 
 
                      
Data are expressed as mean ±SD (n=6). ***denotes statistical significance of MCAo group 
compared with control group at p<0.001. #, # denotes statistical significance of CMU 
(10mg/kg), CUE (10mg/kg) treated groups compared with MCAo group at p<0.05, 
respectively. 
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ELISA 
FIGURE.21. Effect of drug treatment on pro-inflammatory mediator(TNFα) by ELISA 
                      
     
Data are expressed as mean ±SD (n=6). ***denotes statistical significance of MCAo group 
compared with control group at p<0.001. #, # denotes statistical significance of CMU 
(10mg/kg), CUE (10mg/kg) treated groups compared with MCAo group at p<0.05, 
respectively. 
FIGURE.22. Effect of drug treatment on pro-inflammatory mediator(IL 1β ) by ELISA 
                            
 
Data are expressed as mean ±SD (n=6).Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. ***denotes statistical significance 
of MCAo group compared with control group at p<0.001. ##, # denotes statistical significance 
of CMU (10mg/kg), CUE (10mg/kg) treated groups compared with MCAo group at p<0.01, 
p<0.05 respectively. 
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Caspase Activity Assay 
FIGURE.23. Effect of drug treatment on caspase activity assay 
                    
Data are expressed as mean ±SD (n=6). ***denotes statistical significance of MCAo group 
compared with control group at p<0.001. #, # denotes statistical significance of CMU 
(10mg/kg), CUE (10mg/kg) treated groups compared with MCAo group at p<0.05, 
respectively. 
FIGURE.24.A.Effect of drug treatment on BAX & Bcl2 Protein levels 
Bax 
 
 Control    MCAo   CMU(10mg/kg) CUE(10mg/kg)   
Bcl2 
 
 Control       MCAo   CMU(10mg/kg) CUE(10mg/kg) 
β- Actin 
 
Control       MCAo   CMU(10mg/kg) CUE(10mg/kg) 
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FIGURE 25.B..Effect of drug treatment on Bax & Bcl2 levels 
 
 
 
 
Data are expressed as mean ±SD (n=3). Statistical analysis was carried out using One-way 
ANOVA followed by Tukey’s Multiple Comparison Test. *, *** denotes statistical significance 
of MCAo group compared with control group at p<0.05, P<0.001. #, ## denotes statistical 
significance treated groups compared with MCAo group at p<0.05, p<0.01 respectively. 
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6.DISCUSSION 
Estradiol is thought to exert the majority of its biological actions in the body via interaction 
with two primary estrogen receptors: estrogen receptor-alpha (ER-α) and estrogen receptor-
beta (ER-β) (Deroo et al 2006). Both receptors are composed of seven domains, bind E2 with 
high affinity, and they both dimerize and utilize the classical estrogen response elements in a 
similar fashion. However, several differences do exist between ER-α and ER-β, as it has been 
shown that they contain different ligand binding domains, and each receptor is encoded by a 
different gene. In the brain, localization studies have demonstrated that ER-α is localized 
most densely in the hypothalamus, hippocampus, and preoptic area, with moderate to light 
density in the cerebral cortex (McEwen et al., 2001). Conversely, ER-β localization has been 
documented predominantly in the cortex, throughout the hippocampus, in the olfactory bulb, 
septum, preoptic area, nucleus of striata terminalis, amygdala, paraventricular hypothalamus, 
thalamus, ventral tegmental area, substantia nigra and cerebellum (Perez et al., 2003). 
While the majority of the literature appears to support a critical role for ER-α in mediating E2 
neuroprotective effects against cerebral ischemia, there are studies suggesting that ER-β may 
have a neuroprotective role in certain situations. For instance, administration of a selective 
ER-β agonist, WAY 200070-3, has been shown to exert neuroprotection in the rat 
hippocampal CA1 region following GCI (Miller et al.,2005), and another study found that the 
ER-β agonist, DPN, reduced global cerebral ischemia damage in the mouse hippocampal 
CA1 region by 55%.  In the present study, administration of novel ER-β agonist at dose of 
10mg/kg ameliorated the ischemic damage induced by middle cerebral artery occlusion. 
However, evidence of a role for ER-β in mediating endogenous E2 neuroprotection against 
cerebral ischemia is currently lacking, as E2 is fully capable of exerting neuroprotection 
against cerebral ischemia in ER-β knockout mice (Merchenthaler et al.,2005). Nevertheless, 
there is evidence that ER-β may have a role in basal neuronal survival, as it has been reported 
that there is substantial neuronal loss in the brains of ER-β knockout mice at 2 years of age as 
compared to wild type mice (Wang et al., 2001). Being E2 protective there NCE can be noted 
on agonist. 
Several studies have shown that synthetic SERMs, such as tamoxifen, raloxifene or 
bazedoxifene and natural SERMs, like genistein (Azcoitia et al., 2006), are neuroprotective in 
vitro and in vivo. Previous reports suggests that both ERα and ERβ regulated pro-
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inflammatory cytokine and chemokine production through E -dependent and E -independent 
mechanisms (Brown et al., 2010). Estradiol and three ERβ-selective compounds, ERB-041, 
WAY-202196, and WAY-214156, repressed the expression of these inflammatory genes 
TNF-α, IL-6, and CSF2 by recruiting the coactivator, SRC-2 has been proved. Estrogen 
receptors and IGF-I receptors cooperate in neuroprotection in animal models of hippocampal 
neurodegeneration, Parkinson’s disease and global cerebral ischemia (Azcoitia et al., 1999; 
Quesada and Micevych, 2004; Garcia-Segura et al., 2006; Mendez et al., 2006). In addition, 
IGF-I receptor and estrogen receptor activation synergistically increase the activity of the 
kinase Akt and coordinately regulate protection from neurotoxicity downstream of Akt which 
further activates glycogen synthase kinase 3β (GSK3β) (Cardona- Gomez et al., 2004). 
Administration of novel ER-β agonist to MCAo occluded rats did not alter the GSK3β/Akt 
pathway. 
In a recent  study that the silencing of hippocampal ER β - increased inflammasome 
activation; whereas periodic ER- β agonist treatment reduced the activation of the 
inflammasome, consistent with decreased processing of IL- 1β(de Rivero Vaccari et 
al.,2016). Estrogens can also inhibit expression of pro-inflammatory cytokines such as IL-1β 
and TNF-α  in primary astrocytes following LPS exposure (Lewis et al., 2008). In this study, 
novel ER β agonist down regulated the brain IL-1β and TNF-α level suggesting their role in 
controlling neuro inflammation in cerebral ischemic condition. 
Caspase-3, the final executioner of apoptotic cell death mechanism, is a substrate of calpain 
and it becomes active following degradation by calpain, and therefore, up regulated calpain is 
expected to activate caspase-3 in the injured tissue (Gao and Dou.,2000). In our study 
treatment of novel ER β agonist reduced the caspase 3 activity in MCAo rats. 
The selective ERα agonist (propylpyrazole triol, PPT) and ERβ agonist (diarylpropionitrile; 
DPN) are supposed to show similar neuroprotective actions in culture studies. But a previous 
report showed higher neuroprotective potential of the ERα agonist PPT than the ERβ agonist 
DPN (Behl et al., 1995). Some other investigations showed that both PPT and DPN can 
provide neuroprotection against glutamate toxicity by increasing the expression of the anti-
apoptotic Bcl-2 protein and also modulating the stress kinase signaling pathways (Zhao et al., 
2007).  In this study, anti-apoptotic protein bcl2 level were increased and proapoptotic 
protein levels were reduced on administration of novel ER β agonist to MCAo rats. 
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7. SUMMARY & CONCLUSION 
 The objective of the study is to asses the behavioural functions of ER-β stimulation in 
cerebral ischemic condition using novel NCEs. 
 To evaluate the mechanism of neuroprotective activity of ER-β agonist in cerebral ischemia 
by exploring the anti-inflammatory pathways.   
 MCAo was induced by occluding middle cerebral artery under anesthetic condtions and the 
behavaioural parameters were studied after 24 hrs and on 7th day. 
 ER-β  agonist CMU, CUE (10mg/kg) has been assessed for their neuroprotective action.  
 The behavioural parameters include measurement of neurogical deficit through grip strength 
measurement, anxiety beahviour in open feild and elevated plus maze tests. 
 Inducement of MCAo in rats have shown decreased locomtor activity, exploratory, rearing, 
grooming behaviours, indicates inducement of cerebral ischemia have resulted in anxiogenic 
behaviour. 
 Post ischemic administration of CMU, CUE (10mg/kg)  significantly attenuated the 
behavioural in MCAo rats as observed by increased locomotor activity, exploratory & 
grooming behavious, grip strength. 
 Post ischemic administration of CMU, CUE (10mg/kg) significantly reduced the IL-1β, TNF-
α and caspase activity. 
 CUE (10mg/kg) significantly reduced the pro apoptotic Bax & anti apoptotic Bcl2 levels. 
 Novel ER-β agonist has shown neuroprotective effect by downregulating neuro inflammation 
and attenuating apoptotic pathway. 
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